Correspondence 0001193125-24-154245 from Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc.
Date: June 4, 2024 · CIK: 0002012593 · Accession: 0001193125-24-154245
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279486
Letter
June 4, 2024
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
United States Securities and Exchange Commission
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Tamika Sheppard, Joe McCann, Daniel Gordon and Jenn Do
Re: Rapport Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-279486
Acceleration Request
Requested Date: June 6, 2024
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Rapport Therapeutics, Inc. (the “Company”) for acceleration of the effective time of the above-referenced Registration Statement, requesting effectiveness as of 4:00 P.M., Eastern Time, on June 6, 2024, or at such later time as the Company or its outside counsel, Goodwin Procter LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]
Very truly yours,
GOLDMAN SACHS & CO. LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP June 4, 2024 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Attention: Tamika Sheppard, Joe McCann, Daniel Gordon and Jenn Do Re: Rapport Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-279486 Acceleration Request Requested Date: June 6, 2024 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Rapport Therapeutics, Inc. (the “Company”) for acceleration of the effective time of the above-referenced Registration Statement, requesting effectiveness as of 4:00 P.M., Eastern Time, on June 6, 2024, or at such later time as the Company or its outside counsel, Goodwin Procter LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement. We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Signature Page Follows] Very truly yours, GOLDMAN SACHS & CO. LLC JEFFERIES LLC TD SECURITIES (USA) LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED As representatives of the underwriters GOLDMAN SACHS & CO. LLC By: /s/ Dan Parisi Name: Dan Parisi Title: Managing Director JEFFERIES LLC By: /s/ Charles Glazer Name: Charles Glazer Title: Managing Director TD SECURITIES (USA) LLC By: /s/ Bill Follis Name: Bill Follis Title: Managing Director STIFEL, NICOLAUS & COMPANY, INCORPORATED By: /s/ Kenneth Clausman Name: Kenneth Clausman Title: Managing Director